Pharmaceutical Cannabinoids: A Company Update

Time: 2:00 pm
day: Day One Track A - afternoon

Details:

  • Examine re-purposing of dronabinol for the treatment of obstructive sleep apnea (OSA) and other indications
  • Explore completion of two successful Phase 2 clinical trials in OSA
  • Develop lipid nanoparticle formulation to overcome current dronabinol limitations

Speakers: